Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy

Microbial Pathogenesis

Volumn 55, Issue 1, 2013, Pages 9-15

  Beeler, Judy A ^a   Eichelberger, Maryna C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Immunity; Infant; Influenza virus; Respiratory syncytial virus; RSV; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MATERNAL ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

DRUG APPROVAL; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INFLUENZA; NARCOLEPSY; NONHUMAN; NOSE OBSTRUCTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RHINORRHEA; TH2 CELL; UNSPECIFIED SIDE EFFECT; WHEEZING;

ANIMALS; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84872423658     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.11.013     Document Type: Review

References (82)

1. Meissner H.C., Rennels M.B. Unpredictable patterns of viral respiratory disease in children. Pediatrics 2004 Jun, 113(6):1814-1816.
2. Chen Y.W., Huang Y.C., Ho T.H., Huang C.G., Tsao K.C., Lin T.Y. Viral etiology of bronchiolitis among pediatric inpatients in northern Taiwan with emphasis on newly identified respiratory viruses. J Microbiol Immunol Infect 2012, [Epub ahead of print].
3. Respiratory syncytial virus-United States, July 2007-June 2011. Morb Mortal Wkly Rep 2011, 60(35):1203-1206.
4. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98(5):708-715.
5. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378(9807):1917-1930.
6. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
7. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. J Am Med Assoc 1999, 282(15):1440-1446.
8. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
9. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355(1):31-40.
10. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342(4):225-231.
11. Halasa N.B., Gerber M.A., Chen Q., Wright P.F., Edwards K.M. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 2008, 197(10):1448-1454.
12. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342(4):232-239.
13. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemio 1969, 89(4):449-463.
14. Murphy B.R., Prince G.A., Walsh E.E., Kim H.W., Parrott R.H., Hemming V.G., et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986, 24(2):197-202.
15. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(4):422-434.
16. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239(1):149-166.
17. Blanco J.C., Boukhvalova M.S., Shirey K.A., Prince G.A., Vogel S.N. New insights for development of a safe and protective RSV vaccine. Hum Vaccines 2010, 6(6):482-492.
18. Schmidt A.C. Progress in respiratory virus vaccine development. Sem Resp Crit Care Med 2011, 32(4):527-540.
19. Groothuis J.R., Hoopes J.M., Hemming V.G. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011, 28(2):110-125.
20. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102(3 Pt 1):531-537.
21. Wright P.F., Karron R.A., Belshe R.B., Shi J.R., Randolph V.B., Collins P.L., et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007, 25(42):7372-7378.
22. Fisher R.G., Gruber W.C., Edwards K.M., Reed G.W., Tollefson S.J., Thompson J.M., et al. Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics 1997, 99(2):E7.
23. Nguyen M., Ball R., Midthun K., Lieu T.A. The Food and Drug Administration's post-licensure rapid immunization safety monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012, 21(Suppl. 1):291-297.
24. Englund J.A., Walter E., Black S., Blatter M., Nyberg J., Ruben F.L., et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J 2010, 29(2):105-110.
25. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PloS One 2012, 7(3):e33536.
26. Bardage C., Persson I., Ortqvist A., Bergman U., Ludvigsson J.F., Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. Br Med J 2011, 343:d5956.
27. Leroy Z., Broder K., Menschik D., Shimabukuro T., Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012, 30(11):2020-2023.
28. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994, 169(1):68-76.
29. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 1972, 70(4):767-777.
30. Wood J.M., Newman R.W., Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol 2003, 115:9-16.
31. Black S., Nicolay U., Vesikari T., Knuf M., Del Giudice G., Della Cioppa G., et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011, 30(12):1081-1085.
32. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol;10:18.
33. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008 Jul, 15(7):1042-1053.
34. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24(1):157-160.
35. Mbawuike I.N., Wells J., Byrd R., Cron S.G., Glezen W.P., Piedra P.A. HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-gamma, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis 2001, 183(5):687-696.
36. Piedra P.A., Jewell A.M., Cron S.G., Atmar R.L., Glezen W.P. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003, 21(24):3479-3482.
37. PrabhuDas M., Adkins B., Gans H., King C., Levy O., Ramilo O., et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 2011, 12(3):189-194.
38. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev 2007, 7(5):379-390.
39. Adkins B., Leclerc C., Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev 2004, 4(7):553-564.
40. Glezen W.P. Effect of maternal antibodies on the infant immune response. Vaccine 2003, 21(24):3389-3392.
41. Fernandez M.A., Puttur F.K., Wang Y.M., Howden W., Alexander S.I., Jones C.A. T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J Immunol 2008, 180(3):1556-1564.
42. Michaelsson J., Mold J.E., McCune J.M., Nixon D.F. Regulation of T cell responses in the developing human fetus. J Immunol 2006, 176(10):5741-5748.
43. Langrish C.L., Buddle J.C., Thrasher A.J., Goldblatt D. Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin Exp Immunol 2002, 128(1):118-123.
44. Willems F., Vollstedt S., Suter M. Phenotype and function of neonatal DC. Eur J Immunol 2009, 39(1):26-35.
45. Kornete M., Piccirillo C.A. Functional crosstalk between dendritic cells and Foxp3(+) regulatory T cells in the maintenance of immune tolerance. Front Immunol 2012, 3:165.
46. Zaghouani H., Hoeman C.M., Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol 2009, 30(12):585-591.
47. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21(24):3406-3412.
48. Steinhoff M.C., Omer S.B., Roy E., Arifeen S.E., Raqib R., Altaye M., et al. Influenza immunization in pregnancy-antibody responses in mothers and infants. N Engl J Med 2010, 362(17):1644-1646.
49. Shahid N.S., Steinhoff M.C., Roy E., Begum T., Thompson C.M., Siber G.R. Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation. Vaccine 2002, 20(17-18):2404-2409.
50. Wilson W.D., Mihalyi J.E., Hussey S., Lunn D.P. Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination. Equine Vet J 2001, 33(7):644-650.
51. Abdelwhab E.M., Grund C., Aly M.M., Beer M., Harder T.C., Hafez H.M. Influence of maternal immunity on vaccine efficacy and susceptibility of one day old chicks against Egyptian highly pathogenic avian influenza H5N1. Vet Microbiol 2012, 155(1):13-20.
52. Zaman K., Roy E., Arifeen S.E., Rahman M., Raqib R., Wilson E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359(15):1555-1564.
53. Eick A.A., Uyeki T.M., Klimov A., Hall H., Reid R., Santosham M., et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Ped Adol Med 2011, 165(2):104-111.
54. Zuccotti G., Pogliani L., Pariani E., Amendola A., Zanetti A. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine. J Am Med Assoc 2010, 304(21):2360-2361.
55. Fisher B.M., Van Bockern J., Hart J., Lynch A.M., Winn V.D., Gibbs R.S., et al. Pandemic influenza A H1N1 2009 infection versus vaccination: a cohort study comparing immune responses in pregnancy. PloS One 2012, 7(3):e33048.
56. Bulkow L.R., Singleton R.J., Karron R.A., Harrison L.H. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002, 109(2):210-216.
57. Karron R.A., Singleton R.J., Bulkow L., Parkinson A., Kruse D., DeSmet I., et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J Infect Dis 1999, 180(1):41-49.
58. Ogilvie M.M., Vathenen A.S., Radford M., Codd J., Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981, 7(4):263-271.
59. Kasel J.A., Walsh E.E., Frank A.L., Baxter B.D., Taber L.H., Glezen W.P. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. Viral Immunol 1987, 1(3):199-205.
60. Groothuis J.R., Simoes E.A., Hemming V.G. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 1995, 95(4):463-467.
61. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21(24):3465-3467.
62. Markowitz L.E., Albrecht P., Rhodes P., Demonteverde R., Swint E., Maes E.F., et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996, 97(1):53-58.
63. Kitikoon P., Nilubol D., Erickson B.J., Janke B.H., Hoover T.C., Sornsen S.A., et al. The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination. Vet Immunol Immunopathol 2006, 112(3-4):117-128.
64. Gauger P.C., Vincent A.L., Loving C.L., Henningson J.N., Lager K.M., Janke B.H., et al. Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Vet Pathol 2012, 49(6):900-912.
65. Gauger P.C., Vincent A.L., Loving C.L., Lager K.M., Janke B.H., Kehrli M.E., et al. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 2011, 29(15):2712-2719.
66. Vincent A.L., Ma W., Lager K.M., Richt J.A., Janke B.H., Sandbulte M.R., et al. Live attenuated influenza vaccine provides superior protection from heterologous infection in pigs with maternal antibodies without inducing vaccine-associated enhanced respiratory disease. J Virol 2012, 86(19):10597-10605.
67. Barria M.I., Garrido J.L., Stein C.R., Scher E., Ge Y., Engel S.M., et al. Localized mucosal response to LAIV in adults. J Infect Dis 2013 Jan, 207(1):115-124.
68. Ambrose C.S., Wu X., Jones T., Mallory R.M. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 2012, 30(48):6794-6801.
69. Ambrose C.S., Wu X., Knuf M., Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012, 30(5):886-892.
70. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182(5):1331-1342.
71. Collins P.L., Whitehead S.S., Bukreyev A., Fearns R., Teng M.N., Juhasz K., et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999, 54:423-451.
72. Juhasz K., Whitehead S.S., Boulanger C.A., Firestone C.Y., Collins P.L., Murphy B.R. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 1999, 17(11-12):1416-1424.
73. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St Claire M., Elkins W.R., et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999, 73(4):3438-3442.
74. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005, 191(7):1093-1104.
75. Luongo C., Winter C.C., Collins P.L., Buchholz U.J. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 2012, 86(19):10792-10804.
76. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Exp Rev Vaccines 2011, 10(4):539-550.
77. Arulanandam B.P., Mittler J.N., Lee W.T., O'Toole M., Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 2000, 164(7):3698-3704.
78. Esposito S., Pugni L., Daleno C., Ronchi A., Valzano A., Serra D., et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 2011, 127(5):e1161-e1168.
79. Vesikari T., Pepin S., Kusters I., Hoffenbach A., Denis M. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 mo to 17 y of age. Hum Vacc Immunothe 2012, 8(9):1283-1292.
80. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365(15):1406-1416.
81. Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro Surveill;16(26).
82. Han F., Lin L., Warby S.C., Faraco J., Li J., Dong S.X., et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011 Sep, 70(3):410-417.